Skip to main content
Inotuzumab ozogamicin in individuals with Down syndrome and acute lymphoblastic leukemia.
All genetic subtypes of B-cell acute lymphoblastic leukemia exhibit increased incidence rates in children with Down syndrome.
Co-targeting of the thymic stromal lymphopoietin receptor to decrease immunotherapeutic resistance in CRLF2-rearranged Ph-like and Down syndrome acute lymphoblastic leukemia.
5G2 mutant mice model loss of a commonly deleted segment of chromosome 7q22 in myeloid malignancies.
Enhanced Risk Stratification for Children and Young Adults with B-Cell Acute Lymphoblastic Leukemia: A Children's Oncology Group Report.
Correction: Outstanding outcomes with two low intensity regimens in children with low-risk B-ALL: a report from COG AALL0932.
What causes aplastic anaemia?
Outstanding outcomes with two low intensity regimens in children with low-risk B-ALL: a report from COG AALL0932.
Patients with Down syndrome can be included in early phase clinical trials- a report from the T2016-003 Therapeutic Advances in Childhood Leukemia and Lymphoma (TACL) study.
Impact of pre-transplant induction and consolidation cycles on AML allogeneic transplant outcomes: a CIBMTR analysis in 3113 AML patients.